Late outcomes of renal denervation are more favourable than early ones: facts or fancies?
Clinical Kidney Journal · 30.11.2023 · 16 (12) · 2357-2364
DOI: 10.1093/ckj/sfad231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 20.09.2023. Verfasst von Alexandre Persu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Cliniques Universitaires Saint-Luc Université Catholique de Louvain, Brussels, Belgium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Following second-generation randomized trials, there is evidence that renal denervation (RDN) decreases blood pressure (BP), although to a lesser extent than suggested in the initial controlled and observational studies. The recent publication of the 36-month follow-up of the Symplicity HTN-3 trial has raised expectations, suggesting increasing, late benefits of the procedure, despite initially negative results. These findings come after those obtained at 36 months in the sham-controlled trial SPYRAL HTN-ON MED and in the Global Symplicity Registry. However, they are susceptible to biases inherent in observational studies (after unblinding for sham-control) and non-random, substantial attrition of treatment groups at 36 months, and used interpolation of missing BPs. More importantly, in SPYRAL HTN-ON MED and Symplicity HTN-3, long-term BP changes in patients from the initial RDN group were compared with those in a heterogeneous control group, including both control patients who did not benefit from RDN and patients who eventually crossed over to RDN. In crossover patients, the last BP before RDN was imputed to subsequent follow-up. In Symplicity HTN-3, this particular approach led to the claim of increasing long-term benefits of RDN. However, comparison of BP changes in patients from the RDN group and control patients who did not undergo RDN, without imputation of BPs from crossover patients, does not support this view. The good news is that despite the suggestion of sympathetic nerve regrowth after RDN in some animal models, there is no strong signal in favour of a decreasing effect of RDN over time, up to 24 or even 36 months. Still, current data do not support a long-term increase in the effect of RDN and the durability of RDN-related BP reduction remains to be formally demonstrated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Cliniques Universitaires Saint-Luc Université Catholique de Louvain, Brussels, Belgium.
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
- Department of Internal Medicine, Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
- Charité - Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
- University Milano-Bicocca, Milan, Italy.
- Institute of Clinical Medicine, University of Oslo, Departments of Cardiology and Nephrology, Ullevaal Hospital, Oslo, Norway.
ORCID-Profile: Alexandre Persu, Giuseppe Mancia
Zitieren
APA
Persu, A., Stoenoiu, M. S., Maes, F., Kreutz, R., Mancia, G., & Kjeldsen, S. E. (2023). Late outcomes of renal denervation are more favourable than early ones: facts or fancies?. Clinical Kidney Journal, 16(12), 2357-2364. https://doi.org/10.1093/ckj/sfad231
Vancouver
Persu A, Stoenoiu MS, Maes F, Kreutz R, Mancia G, Kjeldsen SE. Late outcomes of renal denervation are more favourable than early ones: facts or fancies?. Clinical Kidney Journal. 2023;16(12):2357-2364. doi:10.1093/ckj/sfad231
BibTeX
@article{Persu2023,
author = {Persu, Alexandre and Stoenoiu, Maria S and Maes, Frédéric and Kreutz, Reinhold and Mancia, Giuseppe and Kjeldsen, Sverre E},
title = {Late outcomes of renal denervation are more favourable than early ones: facts or fancies?},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {12},
pages = {2357--2364},
doi = {10.1093/ckj/sfad231}
}
EUVIMED